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Abstract
Background: The Cochrane Collaboration aims at providing the best available evidence for interventions in health care. We
wished to examine to which extent treatments considered relevant by caregivers in type 2 diabetes are covered by
Cochrane systematic reviews.
Methodology/Principal Findings: 130 different interventions in type 2 diabetes were identified based on a review of clinical
practice guidelines and expert opinion (Table S1). 459 members of the German Diabetes Society (diabetologists, general
practitioners, diabetic nurses, nutritionists, podologists, others) were surveyed via e-mail-list to rank a) the perceived clinical
relevance and b) the perceived need for evidence of interventions, based on an internet survey. In the Cochrane Library,
there were, at the time of this evaluation, 56 reviews on interventions in diabetes. Generally, coverage of topics by Cochrane
reviews reflected the perceived clinical relevance and perceived need for evidence. As an example, highly ranked treatments
such as lifestyle changes or oral antidiabetics were well covered, while low rank treatments such as complementary
approaches were not covered. Discrepancies occurred with new treatments such as amylin-analogues (low relevance, high
need for evidence, review not yet completed) and interventions with immediate and dramatic effects such as treating
hypoglycemia (high relevance, low need for evidence, no review). Also, there was a relative scarcity of reviews concerning
specific problems, in particular, treatment of late diabetic complications.
Conclusions/Significance: For most interventions, perceived relevance and perceived need for evidence are reflected by
the evidence already available. Prioritizing should aim at improving immediacy and consideration of the treatment of
complications.
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Introduction
Clinical research ideally strives to improve the care of patients.
The transfer of knowledge from research to care givers and health
care policy makers is a necessary prerequisite for this to happen.
The mechanisms, quality and determinants of knowledge transfer
have, in consequence, attracted quite some research activity [1–3].
Various projects and organizations aim to improve dissemination
of research results, best known, possibly, the Cochrane Collabo-
ration [4–6].
The Cochrane Collaboration was founded in 1993 with the aim to
easeaccesstoclinicaltrialresults.Sincethen,morethanhalfamillion
citations to clinical trials have been assembled in the Cochrane
Database of Clinical Trials, and more than 3000 systematic reviews
have been prepared for specific health care interventions in the
Cochrane Database of Systematic Reviews. These databases are
published in the Cochrane Library which is now considered one of
the most important sources of evidence in health care.
The success of the Cochrane Collaboration is based on the
enthusiasmof individuals.Reviews are preparedona voluntary basis
by author teams with an interest in a particular research question,
supported by topic-specific editorial teams. The Cochrane Collab-
oration so far had no central board regulating the choice of topics.
Finding ways to prioritize topics for systematic reviews is now
among the major concerns of the Cochrane Collaboration, as
funds are restricted and the collaboration aims at higher
professionalization [7]. It has been estimated that the current
content covers about one third of all systematic reviews required
[8]. This calculation was based on comparing the average number
of clinical trials per review to the overall number of controlled
clinical trials identified. There are a few studies looking into ways
to prioritize research topics, e.g., from the field of public health
[9], emergency medicine and trauma [10,11], nursing [12], or
urinary incontinence [13–15], or using a more general approach
such as in the Database of Uncertainties of the Effects of
Treatments in the UK (http://www.library.nhs.uk/duets/) [16].
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interventions of important health problems are covered in the
Cochrane Library. In particular, we wished to know whether the
priorities set by individual contributors reflect the degree of clinical
relevance as well as need for evidence perceived by professionals
involved in the care of these patients. Type 2 diabetes was chosen
as an example, as this is a disease of high global importance.
Worldwide, about 347 million people are affected, based on a
global adult prevalence of almost 10% in 2008 [17]. The WHO
estimates that current numbers may be expected to double until
the year 2030. Diabetes-related health care expenses are reported
to range from 2.5% to 15% of annual health care budgets and will
rise to pose a relevant economic challenge, in particular to middle-
and low-income countries [18]. Against the background of limited
financial resources an early and effective treatment with a focus on
preventable complications remains essential and a constant issue of
the quality of health care.
Materials and Methods
The study was performed as a combination of an internet survey
of care givers and literature-based data extraction.
Item generation, identification of relevant interventions
Interventions were defined as any procedure or process intended
to improve or change the health status of an individual with type 2
diabetes. Indications included, for example, glycemic control,
prevention of diabetes-specific complications, treatment of compli-
cations, improvement of quality of life and management or
treatment of common co-morbidities. A list was created based on
the clinical situations covered by recommendations in clinical
practice guidelines (included as supplemental material). These were
identified using the international collection of clinical practice
guidelines compiled by the German Physician Center for Quality in
Medicine (A ¨ZQ, Berlin, www.aezq.de). In addition, Medline was
searched via PubMed (diabetes (MeSH and text word) in
combination with the subset ‘‘systematic reviews’’, the publication
type ‘‘clinical practice guideline’’, the text word ‘‘consensus’’ and
the text word ‘‘guideline’’), as well as internet sites for guidelines
(Guidelines International Network (G-IN), Scottish Intercollegiate
Guidelines Network (SIGN) and German Association of the
Scientific Medical Societies (AWMF)). The resulting list of 130
different interventions was grouped as follows (Table S1):
Lifestyle modification, interventions aiming at weight reduction
Complementary and alternative medicine interventions (CAM)
Oral antiglycemic medication (classical, new preparations)
Insulin therapy
Treatment of co-morbidity (dyslipidemia, cardiovascular, neu-
rological/psychiatric)
Treatment of late diabetic complications (diabetic foot,
peripheral neuropathy, kidney, eye)
Treatment of acute diabetic emergencies
Perioperative management
Complex interventions and specialized care
Internet survey
An internet questionnaire was developed using the SelectSurvey
Software (Version 1.5.4, ClassApps). For each intervention,
probands were asked to rate a) the clinical relevance of this
intervention and b) the need for external evidence for this
intervention, given that common indications for the respective
treatment are present. Answers were to be given on a 5-point scale
from extremely important to not important at all (or unknown). An
additional question probed on general attitudes towards and
experience in evidence-based medicine by enquiring on the
frequency of use of different resources, such as the Cochrane
Library or PubMed.
The questionnaire was piloted among a diverse group of six care
givers (one diabetes specialist, one clinical pharmacologist, one
diabetic nurse, one endocrinologist, two general practitioners). No
interventions were reported to be missing or redundant. As the
overall workload for the respondents was felt to be too high, the
questionnaire was divided into two parts: a) clinical relevance, b)
perceived need for evidence. Both parts of the questionnaire
covered the full set of interventions in the same order and
grouping.
The link to the survey was mailed to all members of the German
Diabetes Society (Deutsche Diabetes Gesellschaft, DDG). This
society is the major association of care givers in diabetes in
Germany and includes health care professionals of any discipline,
such as physicians, both specialized and general, researchers,
psychologists, nurses, physiotherapists, podologists, and nutrition-
ists. The exact number of persons on the e-mail list was not
available, but is estimated to be around 2000, including an
unknown proportion of invalid addresses. There was also no
information on the demographic characteristics and specializations
of the list participants. Therefore, differences in the response status
of the list participants could not be ascertained.
Probands were asked to throw a coin and then open either part
1 or 2 of the questionnaire, depending on the result of the thrust.
The titles of the parts of the questionnaires were not revealed
before opening. The order of the two parts (1–2) was changed
midway during the period the survey was open (March 12 to April
29, 2007). Responders were judged to have some (more than
average) experience in evidence-based medicine if they reported a
frequency of use of external evidence (Medline, Cochrane Library)
within the upper half of responses.
The results of the survey were presented using descriptive
analysis (mean, median, and standard deviation for perceived
clinical relevance and perceived need for evidence). In addition,
the proportion of responders considering the intervention very
important or extremely important is shown.
Literature-based data extraction
Reviews dealing with interventions to treat diabetes or diabetic
complications, or dealing with the treatment of other disorders but
specifically aimed at diabetic patients were identified in the
Cochrane Library, issue 1/2008, using the search term diabet*
(title, abstract, keywords). Reviews relating to prediabetes,
gestational diabetes, or type 1 diabetes were excluded, as were
reviews for which the full text was withdrawn and thus not
available online anymore. Reviews were evaluated using a
standardized form. Items assessed included details of the research
question (interventions, comparisons, populations, and outcomes),
as well as details on the inclusion criteria (methods of included
studies) and the results (such as number and quality of included
trials, conclusiveness of the results, adverse events). We also
examined time to completion, measured as time from publication
of a protocol to time of first publication of a review.
Patient subgroups included, for example, children with diabetes,
or patients with obesity, insulin-dependent or insulin-refractory
course, co-morbidities (e.g., dyslipidemia, hypertension, cardio-
vascular problems), acute complications (hypoglycemia, hypergly-
cemia) and long-term complications (e.g., diabetic foot, polyneu-
ropathy, nephropathy, retinopathy), and patients in other/special
situations (e.g., pregnancy, surgery, drug addiction).
Outcomes of reviews were categorized as major (such as
mortality, stroke, myocardial infarction, amputation, loss of vision,
Prioritisation of Clinical Research
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walking distance, episodes of hypoglycemia), performance related
(quality of life, days off work, days in hospital, costs) and surrogate
(glycemic control (glycosylated hemoglobin A, glucose) or any
other measurements in body liquids (hormones, lipids, creatinine
etc), weight/body mass index or blood pressure).
The conclusiveness of the results of a review was categorized as
conclusive (recommendation for or against, equivalence of
treatments), somewhat conclusive (potential recommendation,
recommendation for subgroups only) and inconclusive (‘‘uncer-
tain’’, ‘‘more evidence needed’’).
Ethics
The survey was classified by the local ethics committee as an
evaluation among professionals and as such exempt from ethical
consent. Participation was anonymous and on a voluntary basis.
The evaluation of reviews was based on published materials not
containing individual patient data.
Results
Survey participation
There were 459 responders, rather equally distributed between
the two parts of the survey (229 for perceived clinical relevance/
230 for perceived need for evidence, Table 1). Physicians
specializing in the care of diabetes, as board-certified by the
German Diabetes Society (www.ddg.de), constituted about 50% of
all respondents, followed by specialists in internal medicine/
endocrinology and specialized nurses and support staff. There
were few general practitioners or other doctors without specific
diabetes training in the sample.
Item response varied and was generally lower for rare
interventions (e.g., midodrin in autonomic hypotension, item
response: 137/229; 60%) or new interventions (e.g., exenatid, year
of EMEA approval 2006, item response 150/230; 66%). For most
items, there were between 170 and 179 respondents. There were
no differences in item response rates by professional group,
experience in evidence-based medicine or part of questionnaire
(clinical relevance or need for evidence), but item response
dropped towards the end of the questionnaire.
Results of Cochrane Review assessment
Of 105 reviews identified using the search term diabet* in the
Cochrane Library, 56 completed systematic reviews were found to
be eligible. The remaining reviews did not specifically deal with
diabetes, diabetic patients, or diabetic complications (n=41), or
full texts were unavailable (withdrawn reviews, n=8). In addition,
there were 48 protocols for reviews which would be eligible once
completed. The reviews included, on average, 17 studies (range: 0
to 205, IQR 23 studies). The majority of reviews exclusively dealt
with randomized controlled trials only (43 reviews, 77%). Quasi-
randomized trials were included in 9 reviews (16%), non
randomized trials in 4 reviews (7%), and observational trials in 9
reviews (16%) (categories not mutually exclusive) (Figure S1).
Generally, the inclusion of non randomized and observational
studies, either exclusively or along with randomized trials, was a
feature of reviews on complex interventions and lifestyle
modification; it was not found to occur in reviews on drug
interventions.
Mostly, the quality of included studies was judged by the review
authors to be variable (in 19 reviews) or poor (in 20 reviews), in
only 1 review (2%) the quality was reported to be good. In 17
reviews, the authors did not proceed to carry out meta-analysis
(i.e., there was no statistical pooling of the study results), either due
to lack of studies or due to insufficient quality or due to a high
degree of heterogeneity (author decision). The median time to
completion was 18 months (maximum 120 months). The results of
the meta-analyses were conclusive in 22 reviews (39%), somewhat
conclusive in 25 reviews (44%), and inconclusive in 9 reviews
(16%). All conclusions incorporated a statement that more trials
were needed (100%).
Survey results and corresponding systematic reviews
Lifestyle modifications (10 items) were generally considered
clinically very relevant in the management of diabetes (Table 2). In
particular, physical activity received a mean score of 4.5 and was
considered very important. In contrast, interventions to reduce salt
content, the use of food additives, drug interventions, and surgical
procedures to achieve weight loss were not considered important.
The perceived need for evidence was generally similar to the
perceived clinical relevance in this group. However, for drug
interventions or surgical procedures to achieve loss of weight,
although considered not important (drug: 2.1 (SD 0.77); surgical
1.9 (SD 0.67)), a relatively high need of evidence was perceived
(drug 3.37 (SD 1.10); surgical 3.0 (SD 1.26)).
The group of interventions of lifestyle modification and weight
loss were represented by seven Cochrane reviews, dealing with
weight loss in general, fat content modification, carbohydrate
content modification, physical activity, dietary supplements, and
medical and surgical weight loss interventions. Most reviews used
surrogate parameters such as lipids or weight loss as outcomes.
Major endpoints (mortality, major morbidity) were examined in
only two reviews.
Complementary and alternative interventions (CAM, 5 items)
were considered to be rather unimportant: mean scores ranged
from 1.5 (9/167; acupressure) to 1.9 (3/169; herbal medicines)
(Table 3). The need for evidence was perceived as slightly higher
as compared to the perceived relevance, but generally also quite
low. In the Cochrane Library there is currently one review
available on CAM in a diabetes-related problem, examining the
effect of a Traditional Chinese Medicine intervention on glucose
metabolism.
Of the oral antidiabetic drugs, metformin was among the
highest rated interventions for relevance as well as for need for
evidence (4.4; 4.0) (Table 4). Characteristic for this group of
Table 1. Survey participants.
Part of questionnaire
Professional group
perceived clinical
relevance
perceived need
for evidence
Physicians
Diabetes specialist 107 (51%) 99 (47%)
Endocrinologist, Internist 22 (10%) 46 (22%)
Other specialist 3 (1%) 0
G.P. without diabetes focus 3 (1%) 10 (5%)
not specialized/in training 10 (5%) 9 (4%)
Other
Diabetes nurse/counselor 46 (22%) 32 (15%)
Other professional 19 (9%) 14 (7%)
Patient/relative, consumer 0 2 (1%)
Total number of respondents 229 230
doi:10.1371/journal.pone.0032414.t001
Prioritisation of Clinical Research
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32414interventions, is the frequent use as comparative treatment
(standard therapy) in the evaluation of other therapies. For
example, while there is no review to examine the efficacy of
sulfonyl urea as a primary study question, this treatment is used as
the comparison treatment in 5 reviews. All reviews on oral
diabetics included major outcomes.
More recently introduced preparations are glucagon-like-
peptide analogues (GLP; exenatid, EMEA approval 2006),
dipeptidylpeptidase-4 inhibitors (DPP-4-inhibitors, sitagliptin,
EMEA approval 2007) and amylin analogues (pramlintide, EMEA
approval 2005). All were considered of limited to moderate clinical
relevance, as yet (3.2; 3.1; 2.8) but in high need of evidence (4.4;
4.3; 4.2) (Table 4). In the Cochrane Library there were, at the time
of the survey, no completed reviews on these new interventions.
However, 3 protocols were published (GLP-analogues: 2, DPP-4
inhibitors: 1).
Of the different insulins (12 interventions), humane preparations
(4.2) were considered clinically somewhat more important than the
analogues (short acting, 3.9, long acting 3.7) (not shown). In
contrast, the perceived need for evidence was highest for both
short and long acting analogues (4.3; 4.0; humane preparations
3.8). A discrepancy between perceived relevance and perceived
need for evidence was most pronounced for inhaled insulins (1.7;
3.3). In the Cochrane Library, there were 5 completed reviews on
insulins. All used only surrogate and intermediate endpoints
(glycemic control, hypoglycemic episodes). Respondents also felt
that injection techniques and injection to meal interval were very
important, both clinically and in need of evidence. There are,
however, no reviews or protocols on these issues.
Of the interventions used to correct dyslipidemia in diabetics (6
interventions), only statins were considered both clinically highly
important (4.1) as well as in need of evidence (3.9). For other
preparations, the need for evidence clearly superseded clinical
relevance. Similarly, for the treatment of hypertension (6
interventions), one class was considered clinically particularly
important, as well as in need of evidence (ACE inhibitors/AT1
antagonists: 4.4; 4.1). Beta-blockers, diuretics, calcium antagonist,s
and ‘‘other antihypertensives’’ all ranged between 3.1 to 3.9 for
both relevance and need for evidence. Salt restriction was not
considered important (2.7, perceived need for evidence: 3.2; see
lifestyle interventions). In the Cochrane Library, there was, at the
time of the survey, no completed review on dyslipidemia (1
protocol), there were 2 reviews on the treatment of hypertension in
diabetics and none on other cardiovascular problems (14
interventions, 1 protocol).
Of the complications, the diabetic foot (12 interventions) was
considered most important, in particular with respect to the
treatment of infections (4.7), regular specialist foot care (4.6) and
Table 2. Life style interventions and weight reduction, mean values and percentage attaching high values (%).
Intervention Perceived relevance Perceived need for evidence RP
N mean SD n* (%) N mean SD n* (%)
Physical Activity 179 4.47 0.61 168 (94%) 171 4.10 1.00 138 (81%) 3 1
Weight reduction in general 178 4.17 0.88 146 (82%) 175 3.93 0.98 129 (74%) 4 1
Calory reduction 177 3.89 0.88 117 (66%) 172 3.66 1.05 104 (60%) 0 0
Fat reduction 178 3.70 0.94 107 (60%) 170 3.50 1.01 97 (57%) 1 1
Alcohol/nicotine abstinence 177 3.59 0.93 93 (53%) 169 3.30 1.17 72 (42%) 0 0
Carbohydrate intake modification 177 3.24 0.92 69 (39%) 174 3.67 0.93 102 (59%) 1 2
Salt reduction 177 2.67 0.91 29 (16%) 173 2.96 1.03 52 (30%) 0 0
Food additives 175 1.65 0.78 7 (4%) 171 2.69 1.20 46 (27%) 1 1
Drug interventions for weight reduction 177 2.12 0.77 10 (6%) 171 3.37 1.10 81 (47%) 2 0
Bariatric surgery 178 1.90 0.67 3 (2%) 171 2.98 1.26 60 (35%) 3 0
*number and proportion of respondents considering the interventions as (highly) relevant or/and in high need of evidence.
N: number of overall respondents; n(%): number of respondents (proportion) considering the relevance/need as very high or extremely high.
R: number of reviews (completed); P: number of protocols (planned reviews) in the Cochrane Library.
doi:10.1371/journal.pone.0032414.t002
Table 3. Complementary and alternative methods interventions.
Intervention Perceived relevance Perceived need for evidence RP
N mean SD n* (%) N mean SD n* (%)
Naturopathy, herbal preparations 167 1.87 0.90 9 (5%) 173 2.50 1.15 31 (18%) 0 0
Traditional Chinese Medicine 168 1.69 0.86 6 (4%) 171 2.28 1.19 31 (18%) 1 4
Acupuncture 170 1.64 0.77 5 (3%) 173 2.18 1.14 28 (16%) 0 1
Homeopathy 168 1.63 0.79 4 (2%) 172 2.22 1.15 25 (15%) 0 0
Acupressure 169 1.54 0.68 3 (2%) 173 1.95 1.05 19 (11%) 0 1
*number and proportion of respondents considering the interventions as (highly) relevant or/and in high need of evidence.
N: number of overall respondents; n(%): number of respondents (proportion) considering the relevance/need as very high or extremely high.
R: number of reviews (completed); P: number of protocols (planned reviews) in the Cochrane Library.
doi:10.1371/journal.pone.0032414.t003
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larization (4.0). Walking exercises, skin replacement and physical
therapy were ranked between 3.0 and 3.9 for both clinical
relevance as well as need for evidence. In contrast, drug treatment
such as rheologics (2.9), prostaglandins (2.4) and growth factors
(2.1) were not considered important in the care of patients. These
interventions all scored in the intermediate range for need for
evidence. The importance of the diabetic foot is reflected by 7
completed reviews in the Cochrane Library. Generally, interme-
diate outcomes were used as outcome criteria for this group of
interventions, e.g., reduction of pain or adverse events.
The treatment and prevention of neuropathic complications
encompassesalargerangeofdifferentinterventions(26interventions
identified). Treatments for autonomic neuropathy (e.g., treatment of
erectile dysfunction, gastro paresis or orthostatic dysregulation) were
mostly rated in the lower ranges of clinical relevance. E.g., 5-
phosphodiesteraseinhibitorsforerectile dysfunctionreceivedamean
value of 2.7, alpha liponic acid 2.4 or anticholinergics for orthostatic
dysregulation 2.2. There were only a few exceptions: antiepileptics
for peripheral neuropathy (3.3), medical treatment of glaucoma (3.6)
and physical maneuvers to prevent neuropathic ulcers (taping/
bandages 3.6, positioning of the food 3.3). The need for evidence, in
contrast, was generally high in this group, in particular with respect
to the different drugs used. Evidence for the treatment of
neuropathic complication is limited – there are 7 Cochrane reviews
covering topics such as bandaging, antiepileptics, tricyclics, and 5-
phosphodiesterase inhibitors in diabetes.
Interventions to treat patients with diabetic nephropathy were
generally considered of high clinical relevance, in particular the
treatment of hypertension in patients with nephropathy (4.9), and,
more specifically, use of ACE-inhibitors in diabetic nephropathy
(4.5). The perceived need for evidence correlated well with the
perceived relevance. This was true for drug-treatments (ACE
inhibitors, relevance 4.9, need for evidence 4.3), as well as dietary
restrictions (protein-restriction, 3.4; 4.5), transplantation (3.6; 3.8)
and hemodialysis (4.0, 3.7). The high perceived relevance of this
complication (7 interventions) was not reflected in the Cochrane
Library – there are only 2 completed reviews available (ACE
inhibitors, protein-restriction) (4 protocols). Both included major
outcomes as well as surrogates.
Similar to interventions in nephropathy, interventions in
retinopathy were also considered both important and in need of
evidence. In the Cochrane Library, there are currently 2
completed reviews on retinopathy (drug treatments of retinopa-
thy). Of psychiatric complications and co-morbidity, treatment of
associated dementia and associated depression were considered
clinically relevant as well as in need of evidence. The former is
covered by a Cochrane review.
The results for acute diabetic complications are presented in
Table 5. In hypoglycemia, rapid substitution of glucose was of
eminent clinical importance (4.8), need for evidence was perceived
as less prominent (3.2). In contrast, bicarbonate infusion and
phosphate are considered least important and their need for
evidence intermediate. There are neither completed Cochrane
reviews, nor protocols on acute care interventions in diabetes.
Educating patients in diabetes, diabetes management in general
practice, and general organization of diabetes management were
considered highly important clinically, as well as in need of
evaluation. Generally, training and management issues, both
specific (such as perioperative care, vaccinations, screening) and at
the level of integrated care are somewhat more difficult to define,
so these may have been underrepresented in the survey. There are
currently 16 reviews dealing with these types of intervention and
10 protocols.
Discussion
In this study we explored how caregivers in type 2 diabetes
perceive the relevance and need for evidence for therapeutic
interventions, as assembled from clinical practice guidelines and
expert opinion, and contrasted this to the topics already covered
by systematic reviews. For most interventions, the content of the
Cochrane Database of Systematic Reviews was well in accordance
with the perceived need. Generally, we found that perceived
relevance and perceived need for evidence were similar.
Most reviews examined patient-relevant endpoints. There are a
few notable exceptions, identifying a need for improvement. In
particular, this relates to the immediacy of the reviews, the
consideration of specific subgroups and situations, and the
inclusion of major endpoints in some interventions, notably insulin
analogues.
Deficient immediacy is a common problem in Cochrane reviews
[19–20]. We found a median time from protocol completion to the
publication of the review of 18 months. Overall, the preparation of
a systematic review may well take two years or longer. This is
certainly a point the Cochrane Collaboration needs to work on in
order to better meet the needs of clinicians, in particular with
Table 4. Oral antidiabetics and new medications.
Intervention Perceived relevance Perceived need for evidence RP
N mean SD n* (%) N mean SD n* (%)
Metformin 163 4.35 0.66 148 (91%) 167 3.99 1.04 130 (78%) 5 5
Thiazolidinediones 160 3.36 0.96 76 (48%) 168 4.22 0.84 140 (83%) 5 4
Sulfonylureas 159 3.26 1.07 68 (43%) 167 3.92 1.00 124 (74%) 5 4
Meglitinides 159 3.08 0.99 55 (35%) 169 4.02 0.88 128 (76%) 5 4
Alpha-glucosidase inhibitors 161 2.22 0.99 17 (11%) 170 3.62 1.14 104 (61%) 4 3
GLP analogues 135 3.19 0.94 52 (39%) 158 4.37 0.71 141 (65%) 0 2
DPP 4 inhibitors 130 3.09 0.92 42 (32%) 155 4.33 0.73 135 (87%) 0 0
Amylin analogues 126 2.79 0.98 26 (21%) 154 4.18 0.88 124 (81%) 0 1
*number and proportion of respondents considering the interventions as (highly) relevant or/and in high need of evidence.
N: number of overall respondents; n(%): number of respondents (proportion) considering the relevance/need as very high or extremely high.
R: number of reviews (completed); P: number of protocols (planned reviews) in the Cochrane Library.
doi:10.1371/journal.pone.0032414.t004
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Cochrane authors to identify problems in the conduct of
systematic reviews may be of help to target issues leading to
delays [21].
The quality and usefulness of Cochrane reviews depends on the
endpoints (and quality in general) of the clinical trials available for
inclusion. Most obvious in this survey was a failure to examine
major endpoints in studies on insulin analogues. Also, the very low
proportion of studies considered of good quality was striking.
However, other than often perceived, most reviews arrived at a
conclusive statement. This is in accordance with a previous report
from Cochrane reviews in neonatology [22].
The findings of this review are corroborated by a number of
strengths. We were able to collect opinions from a large group of
persons involved in the daily care of persons with diabetes,
covering a variety of professional groups. The similarity of
opinions across the different groups was striking, evidencing a
high generalizability of the findings on a national level even
though estimates as to the representativeness of the sample are
difficult to provide. As there is no standard way to assess what care
givers would like to see reflected in systematic reviews, we had
chosen two complementary approaches in the survey: asking for
relevance, and asking for perceived need for evidence. The
difference between these two approaches was particularly evident
in the extreme situations of acute emergencies and new drugs:
Giving glucose in hypoglycemic shock was considered clinically
extremely important but less in need of evidence – this is akin to
the notorious parachute example [23].
There are several limitations. First, this was a national survey, at
best representative for the perceptions of care givers in Germany.
Perceptions may differ in other countries. We did not seek the
opinions of consumers (patients with diabetes, family members) or
clinician-patient cooperation in priority setting, as is the focus in
several recent projects [14,24,25]. Similarly, the views of members
of health care management organizations and administrational
bodies were not sought. Our survey was explicitly restricted to
professional care givers in the medical community. Also, there are
some limitations based on the design of the study. Perceived
clinical relevance and perceived need for evidence were rated by
different persons, randomly self-assigned. The concepts were not
specifically defined or explained to the respondents in order to
elicit reactions as spontaneous as possible. There may have been
different concepts of ‘‘need for evidence’’ in different respondents.
Lastly, diabetes is but one topic in the Cochrane Collaboration,
and Cochrane reviews comprise only about 20% of systematic
reviewsavailable inthe literature.Mostofthereviewsidentified were
edited by the Cochrane Metabolic and Endocrine Disorders Group
(http://www.endoc.cochrane.org/de) and follow highly standard-
ized forms prepared by this group. Specific organ complications fall
into the responsibilities of various other Cochrane editorial groups,
such as diabetic nephropathy in the Kidney Group, and diabetic
retinopathy in the Eyes and Vision Group. Therefore, our finding
that patients suffering from late diabetic complications seem to be
underrepresentedinCochraneReviews,ascomparedtotheascribed
clinical relevance, may be a consequence of the specific infrastruc-
ture within the Cochrane Collaboration. This refers to issues of
overlapintheresponsibilitiesofvariousCochraneeditorialgroups.It
may not apply to other disease entities.
In summary, in general, we found diabetic interventions well
covered in the Cochrane Library with some areas for improve-
ment highlighted. We would like to encourage researchers to
acknowledge the priorities set by clinicians and other medical care
givers.
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